Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1471-0528.13028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression.
Pharmaceuticals (Basel)
November 2024
Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
This paper investigates the therapeutic use of PCSK9 inhibitors, particularly Evolocumab, as monoclonal antibodies for the treatment of atherosclerosis based on recent literature reviews. PCSK9 is an outstanding example of a breakthrough in medical science, with advancements in understanding its biological function driving substantial progress in atherosclerosis treatment. Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of mortality, imposing substantial financial burdens on healthcare systems.
View Article and Find Full Text PDFThe Genetic Odyssey of Axolotl Regeneration: Insights and Innovations.
Int J Dev Biol
December 2024
Key Laboratory of Evolution & Marine Biodiversity (Ministry of Education) and Institute of Evolution and Marine Biodiversity, Ocean University of China, Qingdao, China.
The axolotl, a legendary creature with the potential to regenerate complex body parts, is positioned as a powerful model organism due to its extraordinary regenerative capabilities. Axolotl can undergo successful regeneration of multiple structures, providing us with the opportunity to understand the factors that exhibit altered activity between regenerative and non-regenerative animals. This comprehensive review will explore the mysteries of axolotl regeneration, from the initial cellular triggers to the intricate signaling cascades that guide this complex process.
View Article and Find Full Text PDFIntroduction: GNE-myopathy is a distal myopathy with adult-onset and initial involvement of anterior leg compartment. A founder effect has been demonstrated for some patients from several large cohorts in different countries.
Methods: In this study, we investigated the allele frequency of the c.
Contributions of Pediatric Hematology/Oncology to the Diagnosis, Treatment, and Cure of Acute Lymphoblastic Leukemia: Part 2a (Numbers 11 to 15).
J Pediatr Hematol Oncol
January 2025
Division of Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, UT.
Pediatric hematology/oncology as a subspecialty has made major contributions to the diagnosis and treatment of acute lymphoblastic leukemia, the most common malignancy in the pediatric population. This impressive progress has yielded complete response rates of 98%, median durations of complete continuous remissions of over 5 years, and long-term leukemia-free survival and probable cure in 80% to 85% of patients. Sixty-five years ago, such data could only be imagined as future goals.
View Article and Find Full Text PDFGuselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Lancet
January 2025
Department of Medicine I, Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany.
Article Synopsis
- Interleukin-23 inhibition is a promising treatment for ulcerative colitis, and guselkumab serves as a potent inhibitor targeting this pathway, aiming to assess its safety and effectiveness for patients who have not responded to traditional therapies.
- The study included two phase 3 trials where adults with moderate to severe active ulcerative colitis were randomly assigned to receive guselkumab or a placebo, with a focus on clinical remission as the main outcome at specific time points.
- Results showed that a significantly higher number of patients receiving guselkumab achieved clinical remission compared to those on placebo, highlighting its potential as an effective therapy for managing ulcerative colitis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!